NewAmsterdam Pharma Company (NAMS) Stock Forecast, Price Target & Predictions
NAMS Stock Forecast
NewAmsterdam Pharma Company stock forecast is as follows: an average price target of $39.33 (represents a 54.24% upside from NAMS’s last price of $25.50) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
NAMS Price Target
The average price target for NewAmsterdam Pharma Company (NAMS) is $39.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $36.00. This represents a potential 54.24% upside from NAMS's last price of $25.50.
NAMS Analyst Ratings
According to 5 Wall Street analysts, NewAmsterdam Pharma Company's rating consensus is 'Buy'. The analyst rating breakdown for NAMS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NewAmsterdam Pharma Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | Roanna Ruiz | Leerink Partners | $45.00 | $20.01 | 124.89% | 76.47% |
| Sep 23, 2024 | Yasmeen Rahimi | Piper Sandler | $37.00 | $15.95 | 131.97% | 45.10% |
| Aug 28, 2024 | Serge Belanger | Needham | $36.00 | $16.77 | 114.67% | 41.18% |
The latest NewAmsterdam Pharma Company stock forecast, released on Nov 20, 2024 by Roanna Ruiz from Leerink Partners, set a price target of $45.00, which represents a 124.89% increase from the stock price at the time of the forecast ($20.01), and a 76.47% increase from NAMS last price ($25.50).
NewAmsterdam Pharma Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $45.00 | $41.00 | $39.33 |
| Last Closing Price | $25.50 | $25.50 | $25.50 |
| Upside/Downside | 76.47% | 60.78% | 54.24% |
In the current month, the average price target of NewAmsterdam Pharma Company stock is $45.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 76.47% increase as opposed to NewAmsterdam Pharma Company's last price of $25.50. This month's average price target is up 9.76% compared to last quarter, and up 14.42% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 11, 2024 | Jefferies | Buy | Buy | Hold |
| Nov 20, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Oct 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 23, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 23, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 28, 2024 | Needham | Buy | Mixed | Initialise |
| Aug 28, 2024 | Needham | Buy | Initialise | |
| Aug 27, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 15, 2024 | Cowen & Co. | Buy | Initialise |
NewAmsterdam Pharma Company's last stock rating was published by Jefferies on Dec 11, 2024. The company gave NAMS a "Buy" rating, the same as its previous rate.
NewAmsterdam Pharma Company Financial Forecast
NewAmsterdam Pharma Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $19.01M | $20.70M | $22.54M | $24.55M | $1.72M | $1.87M | $1.21M | $1.62M | $2.89M |
| High Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $19.01M | $20.70M | $22.54M | $24.55M | $2.57M | $1.89M | $1.25M | $1.66M | $3.12M |
| Low Forecast | $1.26M | $900.85K | $540.50K | $270.25K | $19.01M | $20.70M | $22.54M | $24.55M | $872.52K | $1.85M | $1.16M | $1.57M | $2.65M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NAMS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
NewAmsterdam Pharma Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $4.59M | $5.00M | $5.44M | $5.92M | $415.92K | $451.84K | $291.09K | $390.74K | $696.73K |
| High Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $4.59M | $5.00M | $5.44M | $5.92M | $621.25K | $457.02K | $301.02K | $401.43K | $752.03K |
| Low Forecast | $304.39K | $217.43K | $130.46K | $65.23K | $4.59M | $5.00M | $5.44M | $5.92M | $210.59K | $446.65K | $281.16K | $380.05K | $639.22K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict NAMS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NewAmsterdam Pharma Company's previous annual EBITDA (undefined) of $NaN.
NewAmsterdam Pharma Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-41.38M | $-39.19M | $-37.10M | $-36.43M | $-39.83M | $-40.48M | $-41.99M | $-42.21M | $-44.83M | $-42.35M | $-50.93M | $-54.48M | $-50.36M |
| High Forecast | $-41.38M | $-39.19M | $-37.10M | $-36.43M | $-39.83M | $-40.48M | $-41.99M | $-39.57M | $-41.24M | $-42.35M | $-50.93M | $-54.48M | $-46.02M |
| Low Forecast | $-41.38M | $-39.19M | $-37.10M | $-36.43M | $-39.83M | $-40.48M | $-41.99M | $-44.85M | $-47.52M | $-42.35M | $-50.93M | $-54.48M | $-58.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NAMS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NewAmsterdam Pharma Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.43M | $1.02M | $611.12K | $305.56K | $21.49M | $23.40M | $25.49M | $27.75M | $1.95M | $2.12M | $1.36M | $1.83M | $3.26M |
| High Forecast | $1.43M | $1.02M | $611.12K | $305.56K | $21.49M | $23.40M | $25.49M | $27.75M | $2.91M | $2.14M | $1.41M | $1.88M | $3.52M |
| Low Forecast | $1.43M | $1.02M | $611.12K | $305.56K | $21.49M | $23.40M | $25.49M | $27.75M | $986.51K | $2.09M | $1.32M | $1.78M | $2.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
NewAmsterdam Pharma Company's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NAMS last annual SG&A of $NaN (undefined).
NewAmsterdam Pharma Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 4 | 1 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.44 | $-0.41 | $-0.39 | $-0.38 | $-0.42 | $-0.43 | $-0.44 | $-0.45 | $-0.47 | $-0.45 | $-0.54 | $-0.57 | $-0.53 |
| High Forecast | $-0.44 | $-0.41 | $-0.39 | $-0.38 | $-0.42 | $-0.43 | $-0.44 | $-0.42 | $-0.44 | $-0.45 | $-0.54 | $-0.57 | $-0.49 |
| Low Forecast | $-0.44 | $-0.41 | $-0.39 | $-0.38 | $-0.42 | $-0.43 | $-0.44 | $-0.47 | $-0.50 | $-0.45 | $-0.54 | $-0.57 | $-0.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, NewAmsterdam Pharma Company's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NAMS previous annual EPS of $NaN (undefined).
NewAmsterdam Pharma Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.28 | $36.00 | 1478.95% | Buy |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| CMPX | Compass Therapeutics | $1.53 | $5.00 | 226.80% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| PRTC | PureTech Health | $21.80 | $57.00 | 161.47% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
| NAMS | NewAmsterdam Pharma Company | $26.61 | $39.33 | 47.80% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| JANX | Janux Therapeutics | $59.61 | $70.25 | 17.85% | Buy |